Novartis and Microsoft revolutionize healthcare with AI-driven collaboration

Protein research copilot using Amazon Bedrock AgentCore

Henry Schein One · Therapeutics research · AWS

Protein researchers face a time-consuming challenge: manually searching through thousands of peptide sequences to find structurally similar candidates is slow, error-prone, and requires deep domain expertise to interpret results. A conversational protein research copilot combines natural-language query parsing, protein embedding generation, vector similarity search, and AI-generated scientific summaries in a single interface.

Multi-agentProduction

Giles AI Accelerates Clinical Research with Google Cloud AI Platform

Giles AI · Therapeutics research · GCP

Giles AI leverages Google Cloud's unified AI ecosystem to accelerate clinical research and improve compliance. The platform uses Document AI to parse unstructured medical literature and Gemini for complex reasoning to ensure high accuracy and trustworthiness. The infrastructure includes Google Kubernetes Engine and Cloud Run to provide low latency, scalable real-time features. Model Garden on Vertex AI enables specialized model deployment for different healthcare use cases.

Phagos Uses Amazon SageMaker Generative AI to Revolutionize Bacterial Infection Treatment

Phagos · Therapeutics research · AWS

Phagos, a Paris-based biotech startup, is pioneering AI-powered phage therapy to combat antibiotic-resistant bacterial infections using generative AI models on Amazon SageMaker to match bacteriophages to specific bacteria. The challenge addressed is the inefficiency and slowness of traditional antibiotic development amid rising antibiotic resistance causing millions of deaths annually. Phagos developed predictive AI models trained on genomic data using Amazon SageMaker, and utilizes Amazon EC2 for computation, Amazon S3 and RDS for scalable and secure data storage, enabling rapid phage-bacteria matching. The AI platform reduced treatment development time from over 10 years to about two months, achieved 99.5% time savings in phage screening, and allowed deployment in animal farming with plans for human use by 2030.

Exploring

Moderna accelerates drug discovery and workforce transformation with AI-driven data ecosystem

Moderna · Therapeutics research · Microsoft

Moderna, a global biotech leader, has pioneered the use of AI across its R&D, manufacturing, and commercialization, fueling its rapid response to COVID-19 and driving breakthroughs in mRNA medicine discovery. The company's CIO, Brad Miller, describes an organizational vision centered on data and AI, treating mRNA as the 'software of life.' By building a proprietary data ecosystem and integrating AI algorithms throughout every business process, Moderna enables personalized drug design, rapid therapy development, and optimized manufacturing. To ensure company-wide adoption, Moderna launched the Moderna AI Academy, democratizing AI upskilling at all levels. Today, Moderna claims its 5,000-employee workforce operates at the capacity of 50,000 through AI-powered digital transformation. AI is leveraged in everything from autonomous design of personalized therapies to supply chain optimization, supporting Moderna's ambitious goals to bring 15 new products to market within five years. This cultural and technological shift aims to maximize patient impact and efficiency using Microsoft's data and AI platforms. The company's experience highlights how end-to-end AI integration can redefine timelines, productivity, and innovation in life sciences. Moderna's journey illustrates benefits for both workforce upskilling and direct business value—faster development, enhanced precision, and new medicine modalities.